08.09.16
Endo International has named Joseph Ciaffoni as president, U.S. Branded Pharmaceuticals, effective August 15, 2016.
Prior to joining Endo, Mr. Ciaffoni served as senior vice president, global specialty medicines group for Biogen. In this role, he led the development and execution of all aspects of global strategy across the value chain for marketed and pipeline products. Mr. Ciaffoni started his employment with Biogen Idec in 2012 and during his tenure held senior roles including senior vice president, U.S. commercial and vice president, U.S. neurology field operations and marketing.
"We are excited to announce the addition of Joe to the Endo executive team,” said Rajiv De Silva, president and chief executive officer, Endo. “His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business.”
Prior to joining Endo, Mr. Ciaffoni served as senior vice president, global specialty medicines group for Biogen. In this role, he led the development and execution of all aspects of global strategy across the value chain for marketed and pipeline products. Mr. Ciaffoni started his employment with Biogen Idec in 2012 and during his tenure held senior roles including senior vice president, U.S. commercial and vice president, U.S. neurology field operations and marketing.
"We are excited to announce the addition of Joe to the Endo executive team,” said Rajiv De Silva, president and chief executive officer, Endo. “His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business.”
